Immix Biopharma, Inc.
IMMX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001873835
No open-market purchases or sales by Immix Biopharma, Inc. insiders were filed in the last 90 days; 109 institutions reported holding it in 13F filings for Q2 2026, worth $579.6M in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Immix Biopharma, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 18 | 12 | −6 |
| Shares | 440.8K | 400.8K | −40.0K (−9.1%) |
| Value | $1.01M | $729.8K | −$281.4K (−27.8%) |
New holders (3)
Institutions that held Immix Biopharma, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Umb Bank N A | 99,300 | $180.7K | 0.00% |
| Susquehanna International Group, LLP | 17,723 | $32.3K | 0.00% |
| Ground Swell Capital, LLC | 10,692 | $19.5K | 0.03% |
Sold out (9)
Institutions that held Immix Biopharma, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Murchinson Ltd. | 67,200 | $153.9K |
| Boothbay Fund Management, LLC | 33,600 | $76.9K |
| Lynwood Capital Management Inc. | 25,000 | $58.0K |
| Northern Trust Corp | 19,151 | $43.9K |
| Bank of Montreal | 15,000 | $36.0K |
| Two Sigma Securities, LLC | 12,597 | $28.8K |
| Bank of America Corp | 10 | $22 |
| FMR LLC | 7 | $16 |
| Morgan Stanley | 1 | $2 |